msdialogue Magazine -Summer 2011 Vol. 12 No. 1 - facebook prikbord

In the Summer 2011, Vol. 12, No.1 issue of msdialogue there is only one article regarding CCSVI.

Shared Solutions®, MSWatch®, and msdialogue® are trademarks of Teva Canada Innovation. © 2011, Teva Canada Innovation G.P.-S.E.N.C., Montreal, Quebec | This site is intended for Canadian residents only.

So with this in mind, I can paraphrase that they list CCSVI study highlights of Dr. Robert Zivadinov, University of Buffalo, USA; Dr. Katayoun Alikhani, University of Calgary, Alberta, Canada; Dr. Florian Connolly, Humboldt University, Berlin, Germany; Dr. Florian Doepp, University Hospital Charite, Berlin, Germany; and Dr. Christopher Mayer, Goethe University, Frankfurt, Germany.

The results of these studies were from Neurology 2011 Apr 13, AAN 2011, Abstract S01.006, AAN 2010; Abstract S01.001, Annals of Neurology 2010;68: 173-183 and AAN 2011; Abstract 01.002; Neurology 2011; 76: A171.

These 5 studies indicated low percentages of participants showing prevalence of CCSVI; low percentages of participants with neck vein abnormalities with and without MS; none having venous blood reflux except one participant; none had signs of venous narrowing except one with abnormal venous blood flow direction; and none having blood flow abnormality in either MS or control participants and less than half of controls and patients with narrowing of the internal jugular veins.

They purposely chose these particular studies for their one and only article on CCSVI. msdialogue magazine is published twice a year by Tamarind Healthcare Communications Inc.

http://www.manta.com/ic/mtqs4j5/ca/tamarind-healthcare-communications-inc

and

http://www.tamarindhealthcare.ca/clare.html

and

Third Party Publications: Third Party Publications: Turn the page to success! From position papers to quarterly newsletters, peer to PAAB review, our custom publications cover all the bases. Leverage our network of contacts to find the ideal medium for your marketing objectives.

http://www.tamarindhealthcare.ca/publications.html

through an educational grant from Teva Canada Innovation. Teva and the design version thereof are registered trademarks of Teva Pharmaceutical Industries Ltd. and are used under licence.

As far as Teva Canada Innovation goes, check out their website:

?http://tevacanadainnovation.com/English/about/company_background.aspx

Teva Pharmaceutical Industries Ltd., our parent company, was founded as a wholesale drug business in 1901 in Jerusalem. Teva started building local pharmaceutical plants in Israel in 1930.

After a rich and successful history of acquisitions, mergers and joint ventures, today Teva Pharmaceutical Industries Ltd. is one of the top 15 pharmaceutical companies in the world, specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals, as well as active pharmaceutical ingredients.

With operations in over 60 countries and over 60,000 employees worldwide, the company offers the widest range of cost-effective pharmaceuticals, both generic and branded, to consumers, customers and healthcare providers.

Teva’s Innovative R&D efforts are currently focused on therapies for the central nervous system (with a focus on Multiple Sclerosis), autoimmune diseases and oncology.....(read more at their site).

There is no doubt as to why they post negative studies regarding CCSVI in their magazine. Teva is also the manufacturer of Copaxone. The back cover is a full page ad by the MS Society of Canada for their MS bike tour, a huge Canada wide fundraiser for the MS Society.

On the front cover of the magazine it says msdialogue - for those whose lives are affected by MS. This is hypocrisy, disceptive, and treacherous.

Shirl